AZD5148

DRUG4 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Clostridioides Difficile InfectionHealthy ParticipantsRecurrence of Clostridioides difficile Infection

Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

CompletedNCT06469151

AstraZenecaHealthy Participants

Start: 2024-06-24End: 2025-10-22Updated: 2025-11-10

Safety and Tolerability of AZD5148 in Japanese Participants

CompletedNCT06639997

AstraZenecaClostridioides Difficile Infection

Start: 2024-10-31End: 2025-12-25Updated: 2026-01-30

Phase 2

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

RecruitingNCT07285213

AstraZenecaClostridioides Difficile Infection

Start: 2025-12-10End: 2028-01-18Target: 230Updated: 2026-09-10

A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above

Not yet recruitingCTIS2025-521416-19-00

AstraZeneca ABRecurrence of Clostridioides difficile Infection

Target: 71Updated: 2026-02-17